Based on phase III trial outcomes, tirzepatide, a bifunctional glucose-dependent insulinotropic polypeptide receptor and GLP-1 receptor agonist, gained FDA approval for treating adults with type 2 diabetes [53,54,55]. Here, GIPR is linked to type 2 diabetes mellitus.